1. Home
  2. DXC vs WGS Comparison

DXC vs WGS Comparison

Compare DXC & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DXC Technology Company

DXC

DXC Technology Company

HOLD

Current Price

$13.33

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$69.80

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
DXC
WGS
Founded
1959
2017
Country
United States
United States
Employees
130000
1300
Industry
EDP Services
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
DXC
WGS
Price
$13.33
$69.80
Analyst Decision
Hold
Strong Buy
Analyst Count
8
7
Target Price
$15.14
$130.71
AVG Volume (30 Days)
2.6M
636.2K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
356.52
N/A
EPS
0.88
N/A
Revenue
$12,871,000,000.00
N/A
Revenue This Year
N/A
$29.98
Revenue Next Year
N/A
$25.92
P/E Ratio
$14.75
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$11.23
$55.17
52 Week High
$17.26
$170.87

Technical Indicators

Market Signals
Indicator
DXC
WGS
Relative Strength Index (RSI) 60.48 50.72
Support Level $12.72 $68.55
Resistance Level $14.80 $95.75
Average True Range (ATR) 0.59 4.23
MACD 0.13 1.45
Stochastic Oscillator 90.81 81.62

Price Performance

Historical Comparison
DXC
WGS

About DXC DXC Technology Company

DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: